Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 410

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 410
---
 |            5.10 |
|                                                                                        |     |       74,147 |     |          93,950 |     | (8             | ) |     | (36,428           | ) |     |              131,661 |     |   |                 |
| Options exercisable at 31 December 2021                                                |     |              |     |                 |     |                |   |     |                   |   |     |                      |     |   |           8,982 |
| Weighted average exercise price of outstanding options at 31 December 2021             |     |              |     |                 |     |                |   |     |                   |   |     |                      |     | £ |          10.759 |
| Weighted average exercise price of options exercised in 2021                           |     |              |     |                 |     |                |   |     |                   |   |     |                      |     |   |             n/a |
| Weighted average exercise price of options lapsed in 2021                              |     |              |     |                 |     |                |   |     |                   |   |     |                      |     | £ |       1,676.000 |
| Weighted average exercise price of options forfeited in 2021                           |     |              |     |                 |     |                |   |     |                   |   |     |                      |     | £ |           8.955 |
| Weighted average exercise price of options granted in 2021                             |     |              |     |                 |     |                |   |     |                   |   |     |                      |     | £ |           5.515 |
| Weighted average remaining contractual life of outstanding options at 31 December 2021 |     |              |     |                 |     |                |   |     |                   |   |     |                      |     |   |       9.0 years |

| F-74 |

| 24 | Share-based payments (continued) |

The following information
is relevant in the determination of the fair value of options granted during the year 2022 under the equity share based remuneration schemes
operated by the Group.

| Schedule of fair value of options granted |     |   |               |     |     |   |               |     |     |   |               |     |
|                                           |     |   | February 2022 |     |     |